A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Running, not enrolling · Phase 1 · Has a placebo group

Conditions studied: Epstein-Barr Virus Infection

In brief

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Key facts

Study ID
NCT05831111
Run by
ModernaTX, Inc.
People needed
482
Starts
2023-04-05
Expected to finish
2026-10-07
Last updated by the study team
2025-09-30

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.